

CLAIM AMENDMENTS

1 1. (original) Liquid crystal gel for use in the
2 manufacture of transdermal pharmaceutical compositions and healing
3 cosmetics characterized in that the gel containing
4 polyoxyethyleneglyceryl-trioleate, propylene-glycol, isopropyl
5 myristate and a hyaluronic acid salt or complex.

1 2. (original) The liquid crystal gel for use in the
2 manufacture of transdermal pharmaceutical compositions and healing
3 cosmetics according to claim 1 characterized in that the amount of
4 polyoxyethylene-glyceryl-trioleate in the gel varies between 26.7
5 and 40% (w/w) of the total weight of the gel.

3. (canceled)

4. (canceled)

1 5. (original) The liquid crystal gel for use in the
2 manufacture of transdermal pharmaceutical compositions and healing
3 cosmetics according to any of claims 1-4 characterized in that the
4 amount of propylene-glycol added to the gel varies between 13.3 and
5 20% (w/w) of the total weight of the gel.

6. (canceled)

7. (canceled)

1 8. (original) The liquid crystal gel for use in the
2 manufacture of transdermal pharmaceutical compositions and healing
3 cosmetics according to any of claims 1-7 characterized in that the
4 ratio of polyoxyethylene-glyceryl-trioleate and propylene-glycol is
5 2 : 1.

1 9. (original) The liquid crystal gel for use in the
2 manufacture of transdermal pharmaceutical compositions and healing
3 cosmetics according to any of claims 1-8 characterized in that the
4 amount of isopropyl-myristate added to the gel varies between 5 and
5 35% (w/w) of the total weight of the gel.

10. (canceled)

11. (canceled)

1 12. (original) The liquid crystal gels for use in the
2 manufacture of transdermal pharmaceutical compositions and healing
3 cosmetics according to any of claims 1-11 characterized in that
4 sodium-hyaluronate is applied as hyaluronic acid salt.

1 13. (original) The liquid crystal gels for use in the
2 manufacture of transdermal pharmaceutical compositions and healing

3 cosmetics according to any of claims 1-11 characterized in that
4 hyaluronic acid zinc complex is applied as hyaluronic acid complex.

1 14. (original) The liquid crystal gel for use in the
2 manufacture of transdermal pharmaceutical compositions and healing
3 cosmetics according to any of claims 12-13 characterized in that
4 the amount of sodium-hyaluronate or hyaluronic acid zinc complex in
5 the gel varies between 0.01 and 2% (w/w) of the total weight of the
6 gel.

15. (canceled)

16. (canceled)

1 17. (original) Transdermal pharmaceutical composition
2 characterized in that the composition consists of an estrogen and
3 progestin component as well as a liquid crystal gel containing
4 polyoxyethylene-glyceryl-trioleate, propylene-glycol, isopropyl
5 myristate and a hyaluronic acid salt or complex.

1 18. (original) The pharmaceutical composition according
2 to claim 17 characterized in that the estrogen component is
3 estradiol.

19. (canceled)

1 20. (original) The pharmaceutical composition according
2 to any of claims 17-19 characterized in that the progestin
3 component is gestodene.

21. (canceled)

1 22. (original) The pharmaceutical composition according
2 to any of claims 17-19 characterized in that the progestin
3 component is etonogestrel.

23. (canceled)

1 24. (original) The pharmaceutical composition according
2 to any of claims 17-19 characterized in that the progestin
3 component is levonorgestrel.

25. (canceled)

1 26. (currently amended) Method of treatment for A method
2 of treating a patient for moderate to severe vasomotor symptoms, as
3 well as hot flashes, nocturnal sweating, and palpitation due to
4 post-menopausal estrogen deficiency, which comprises the step of
5 transdermally administering to the skin of the patient transdermal
6 hormone replacement therapy characterized in that a therapeutically
7 effective amount of a pharmaceutical composition for hormone
8 replacement which consists essentially of an estrogen and a

9 progestin component as well as a liquid crystal gel containing
10 polyoxyethylene-glyceryl-trioleate, propylene-glycol, isopropyl
11 myristate and a hyaluronic acid salt or complex is applied onto the
12 surface to be treated.

27. (Canceled)

1 28. (original) Transdermal pharmaceutical composition
2 characterized in that the composition consists of one or more
3 active agent components as well as a liquid crystal gel containing
4 polyoxyethylene-glyceryl-trioleate, propylene-glycol, isopropyl
5 myristate and a hyaluronic acid salt or complex.

1 29. (original) The pharmaceutical composition according
2 to claim 28 characterized in that the active agent component is
3 ondansetron.

30. (canceled)

1 31. (original) The pharmaceutical composition according
2 to claim 28 characterized in that the active agent component is
3 terbinafine.

32. (canceled)

1 33. (original) The pharmaceutical composition according
2 to claim 28 characterized in that the active agent component is
3 fluconazole.

34. (canceled)

1 35. (original) The pharmaceutical composition according
2 to claim 28 characterized in that the active agent component is
3 metronidazole.

36. (canceled)

1 37. (original) The pharmaceutical composition according
2 to claim 28 characterized in that the active agent component is
3 fentanyl.

38. (canceled)

1 39. (original) The pharmaceutical composition according
2 to claim 28 characterized in that the active agent component is
3 nandrolone decanoate.

40. (canceled)

1 41. (original) The pharmaceutical composition according
2 to claim 28 characterized in that the active agent component is
3 nestorone.

42. (canceled)

1 43. (original) The pharmaceutical composition according
2 to claim 28 characterized in that the active agent component is
3 norethisterone.

44. (canceled)

1 45. (original) The pharmaceutical composition according
2 to claim 28 characterized in that the active agent component is
3 eperisone.

46. (canceled)

1 47. (original) The pharmaceutical composition according
2 to claim 28 characterized in that the active agent component is
3 tolperisone.

48. (canceled)

1 49. (original) The pharmaceutical composition according
2 to claim 28 characterized in that the active agent component is
3 **vinpocetine.**

50. (canceled)

1 51. (original) The pharmaceutical composition according
2 to claim 28 characterized in that the active agent component is
3 **ketamine.**

52. (canceled)

1 53. (original) The pharmaceutical composition according
2 to claim 28 characterized in that the active agent component is
3 **vincristine.**

54. (canceled)

1 55. (original) The pharmaceutical composition according
2 to claim 28 characterized in that the active agent component is
3 **vinblastine.**

56. (canceled)

57. (canceled)

58. (canceled)

59. (canceled)

60. (canceled)

61. (canceled)

62. (canceled)

63. (canceled)

64. (canceled)

65. (canceled)

66. (canceled)

67. (canceled)

68. (canceled)

69. (canceled)

70. (canceled)